• Explore /
  • Poster
  • / Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).

Abstract Poster

Authors

null

Masatoshi Kudo

Department of Gastroenterology and Hepatology, Kindai University School of Medicine, Osaka, Japan

Masatoshi Kudo , Richard S. Finn , Manabu Morimoto , Kun-Ming Rau , Masafumi Ikeda , Chia-Jui Yen , Peter R. Galle , Josep M. Llovet , Bruno Daniele , Ho Yeong Lim , Kun Liang , Kenta Shinozaki , Chunxiao Wang , Reigetsu Yoshikawa , Paolo Abada , Ryan C. Widau , Andrew X. Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT01140347, NCT02435433

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 549)

Abstract #

549

Poster Bd #

D10

Abstract Disclosures

Similar Posters

First Author: Josep M Llovet

First Author: Peter R. Galle

First Author: Maria Reig

First Author: Richard S. Finn